Medline's stock experienced a surge of 40% during its inaugural trading session on Wednesday, closing at $40.66 per share.
This impressive debut followed the medical supply giant's successful initial public offering (IPO), which generated $6.26 billion, marking it as the largest IPO 2025. The strong investor response came on one of the final trading days of the year.
Medline IPO Details
Late Tuesday, Medline announced the pricing of its IPO, revealing that it had sold over 216 million shares at $29 apiece. The Medline initial public offering immediately generated significant interest.
With approximately 1.3 billion Class A shares outstanding, Medline's market capitalization exceeded $50 billion at the close of trading on Wednesday. This valuation reflects strong investor confidence in the company's future prospects.
In 2021, private equity firms Blackstone, Carlyle, and Hellman & Friedman acquired a majority stake in Medline, valuing the company at $30 billion. This prior investment laid the groundwork for the company's successful public offering.
Financial Performance and Future Outlook
Medline's financial performance in the first nine months of 2025 demonstrated solid growth. Revenue reached $20.6 billion, an increase from $18.7 billion during the same period the previous year. Net income also rose from $977 million to $1.02 billion.
The Medline deal caps off what has been the best year for the IPO market since 2021. The outlook for deals and new issues on Wall Street is anticipated to be even stronger moving into 2026. Several high-profile companies are rumored to be considering going public.
Potential Future IPOs
Rumors suggest that SpaceX is considering an IPO in 2026, following a recent deal allowing insiders to sell stock in Elon Musk's company, valuing it at $800 billion.
Major artificial intelligence firms such as OpenAI and Anthropic are also reportedly exploring the possibility of going public within the next 18 months. Additionally, database company Databricks, recently valued at $134 billion, has indicated that it may pursue a public offering as early as next year.
The 2025 IPO market success might spur more companies to pursue IPOs in the near future.
Key Takeaways: Medline Stock Price and Performance
- Medline IPO: The medical supply giant raised $6.26 billion in the largest IPO 2025.
- Medline stock price: Shares surged 40% on their first day of trading, closing at $40.66.
- Market Capitalization: Medline's market cap exceeded $50 billion after its successful IPO.
- Financial Growth: The company experienced revenue and net income growth in the first nine months of 2025.
| Metric | 2025 (First 9 Months) | 2024 (First 9 Months) |
|---|---|---|
| Revenue | $20.6 Billion | $18.7 Billion |
| Net Income | $1.02 Billion | $977 Million |
The Medline initial public offering has set a high bar, and the Medline stock price performance will be closely watched in the coming months.
FAQs
What was the Medline stock price at the end of its first day of trading after its initial public offering?
Medline's stock price closed at $40.66 per share on its first day of trading, representing a 40% surge after its IPO. The Medline initial public offering was priced at $29 a share.
How significant was the Medline IPO compared to other IPOs in 2025?
The Medline IPO, which raised $6.26 billion, was the largest IPO 2025. This made it a landmark event in what has been the best year for the IPO market since 2021.
What is Medline's market capitalization following its successful 2025 IPO?
Following its successful IPO, Medline's market capitalization exceeded $50 billion. This valuation reflects strong investor confidence in the company's future prospects and the success of the Medline IPO.
You've got the context, now make it count. Put your knowledge to work and discover potential opportunities in crypto premarket on Whales Market.